Tiger Brokers

BUZZ-Dianthus Therapeutics rises after mid-stage trial win for muscle-weakening drug

Reuters
Sep 08
BUZZ-Dianthus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after mid-stage trial win for muscle-weakening drug

** Shares of drug developer Dianthus Therapeutics DNTH.O rise 17% to $31 premarket

** DNTH's experimental drug claseprubart improved symptoms in adults with generalized myasthenia gravis in a mid-stage trial, company says

** The 13-week trial enrolled 65 patients, and patients received shots under the skin every two weeks at either 300 mg, 600 mg, or a placebo

** Both doses of the drug led to statistically significant improvements in daily function and muscle strength, starting as early as the first week and sustained through week 13

** Dianthus plans to meet U.S. regulators after this Phase 2 study and aims to start a late-stage trial in 2026

** As of last close, DNTH stock up 21.6% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10